Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

BearDownAZ

Jun 05, 2017 09:09AM

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

Nextblockbuster

Jun 05, 2017 11:22AM

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

BearDownAZ

Jun 05, 2017 12:01PM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

in response to

Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

BearDownAZ

posted on Jun 06, 2017 10:09AM

Yesterday I wrote "It's not clear to me if the BIO International Corporate Update is a webcast. Anyone see any info either way?" I emailed both Resverlogix and Zenith about this. I quickly got an response from Clayton indicating "Neither company will be webcasting at BIO International." So hopefully either a news release that afternoon or some very detailed slides shed some light on the various facets of both companies on June 19th and 20th.